Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management.

Cancers·2026
Same author

Connecting Patients with Clinical Trials Using Patient Navigation: A Scoping Review.

Current oncology (Toronto, Ont.)·2026
Same author

Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease.

eLife·2026
Same author

Analysis of interprofessional education perceptions at the team level: A study across three student cohorts.

Journal of interprofessional education & practice·2026
Same author

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Current oncology (Toronto, Ont.)·2026
Same author

Translational evidence for increased central amygdala IL-6 activity in alcohol dependence.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: Sep 13, 2025

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

10.9K

Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian

Angela Chan1, Nancy Nixon2, Muna Al-Khaifi3

  • 1Faculty of Medicine, BC Cancer, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Current Oncology (Toronto, Ont.)
|July 25, 2025
PubMed
Summary

Optimizing adjuvant treatment for hormone receptor-positive, HER2- early breast cancer requires innovative multidisciplinary care models. These models, led by various healthcare professionals, enhance patient monitoring and treatment adherence for better outcomes.

Keywords:
CDK4/6 inhibitorsGPO-led careHR+, HER2–NP-led careadherence managementearly breast cancermultidisciplinary care modelsnurse-led careoncology care optimizationpatient-centered carepharmacist-led careteam-based caretoxicity management

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.6K

Related Experiment Videos

Last Updated: Sep 13, 2025

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

10.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.6K

Area of Science:

  • Oncology
  • Healthcare Management
  • Pharmacology

Background:

  • The adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) is complex and evolving.
  • Advances in therapies like CDK4/6 inhibitors improve outcomes but present significant implementation and monitoring challenges for medical oncologists.

Purpose of the Study:

  • To provide a comprehensive playbook of multidisciplinary-team-based care models for optimizing adjuvant treatment delivery in EBC.
  • To address the logistical and capacity challenges in managing complex EBC therapies.

Main Methods:

  • Review of real-world evidence and successful applications of care models in Canadian centers.
  • Exploration of models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists.
  • Analysis of strategies for managing treatment toxicities, adherence, and patient education.

Main Results:

  • Multidisciplinary models led by nurses, NPs, GPOs, and pharmacists can effectively manage adjuvant treatment complexities.
  • These models leverage team expertise to improve patient care, adherence, and education.
  • Implementation strategies, benefits, and challenges, often supported by quantitative metrics, are detailed.

Conclusions:

  • Innovative, multidisciplinary care models are essential for sustainable and optimal adjuvant treatment delivery in HR+, HER2- EBC.
  • These flexible models can be tailored to local resources and patient needs, inspired by successful examples.
  • The playbook aims to guide breast cancer care teams in enhancing adjuvant management nationwide.